Campus Berlin-Buch in the northern part of Berlin is an innovative science, health and biotechnology park with a high international reputation. Among the unique features of the campus are the clear focus on biomedicine and the spatial proximity and close collaboration of research institutions, clinical research and biotech companies. Research activities focus on the molecular causes of cancer, cardiovascular and neurodegenerative diseases as well as systems biology. Other areas include interdisciplinary basic research to develop new drugs, patient-oriented clinical research and the commercialization of biomedical research results. Investments of more than 439 million euros from the federal and state governments and from the EU have enabled the tradition-rich Campus Berlin-Buch to become an innovative location with an attractive infrastructure and international flair.
Excellent Science and Innovations for Health
With the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) and the Leibniz-Institut für Molekulare Pharmakologie (FMP) as institutions of basic research, the Experimental and Clinical Research Center (ECRC), which is specialized in clinical research and is jointly run by the MDC and Charité – Universitätsmedizin Berlin, and the BiotechPark Berlin-Buch with 56 companies, the 32-hectare campus has outstanding innovation and growth potential. These cooperative ties are leading to increasingly better, marketable methods in the diagnosis and treatment of diseases. The impact of the research location Berlin-Buch on the economic development and the job market situation for Berlin as a whole is increasing.
Clinical maximum care institutions near the campus such as the privately run HELIOS Klinikum Berlin-Buch and the Evangelischen Lungenklinik Berlin (ELK) and Immanuel Krankenhaus Berlin round out this potential in an ideal way.
The overall development of the site has been coordinated by BBB Management GmbH Campus Berlin-Buch since 1995.